AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
NuCana to present abstract on NUC-7738 and PD-1 inhibition synergy at ESMO Congress.
ByAinvest
Wednesday, Sep 3, 2025 8:11 am ET1min read
NuCana plc will present a poster at the upcoming ESMO Congress 2025 in Berlin, Germany. The poster, titled "Patient Derived Organoids Reveal Synergy Between NUC-7738 and PD-1 Inhibition in Renal Cell Cancer," will be presented on Sunday, October 19, 2025. The abstract will be published online via the ESMO website on October 13, 2025.
NuCana plc, a clinical-stage biopharmaceutical company, will present data at the upcoming European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany. The presentation, titled "Patient Derived Organoids Reveal Synergy Between NUC-7738 and PD-1 Inhibition in Renal Cell Cancer," will take place on Sunday, October 19, 2025. The abstract will be published online via the ESMO website on October 13, 2025 [1].NuCana's presentation will focus on the synergy between its novel anti-cancer agent, NUC-7738, and PD-1 inhibitors in the treatment of renal cell cancer. NUC-7738 is a Phase 2 part of a Phase 1/2 study evaluating it as a monotherapy in patients with advanced solid tumors and in combination with pembrolizumab in patients with melanoma. The study aims to demonstrate the potential of NUC-7738 in enhancing the efficacy of PD-1 inhibitors [1].
The company is also conducting a Phase 1b/2 modular study (NuTide:303) evaluating NUC-3373, a new chemical entity derived from 5-fluorouracil, in combination with pembrolizumab for patients with advanced solid tumors and in combination with docetaxel for patients with lung cancer [1].
The presentation at ESMO Congress 2025 is a significant milestone for NuCana, providing an opportunity to showcase its innovative approach to cancer treatment. The company's proprietary technology, ProTide, transforms conventional chemotherapy agents into more effective and safer medicines by generating higher concentrations of anti-cancer metabolites in cancer cells [1].
For more information, please contact NuCana plc or ICR Healthcare.
References:
[1] https://www.globenewswire.com/news-release/2025/09/03/3143493/0/en/NuCana-to-Present-Data-on-NUC-7738-s-Synergy-with-PD-1-Inhibitors-at-the-ESMO-Congress-2025.html
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet